New Digital Radiography, Fluoroscopy, MRI and CT solutions are designed to enhance operational efficiency and transform patient care
Lexington, Mass., November 22, 2023 – FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, is unveiling several new medical systems at the 2023 Radiological Society of North America (RSNA) annual meeting, booth #1929, held November 26 – 30 at McCormick Place in Chicago. The new imaging systems that will be on display include three new digital radiography (DR) suites, two new fluoroscopy systems, a 0.4T MRI system and a 128- slice computed tomography (CT) system.
“At Fujifilm, we believe that a patient’s health journey is a continuous cycle that never stops evolving, and so we continue to engineer our extensive healthcare portfolio around that same philosophy” said Henry Izawa, president and chief executive officer, FUJIFILM Healthcare Americas Corporation. “We’re excited to spend time with industry leaders at RSNA to demonstrate how our leading-edge technologies spanning multiple modalities and enterprise imaging solutions support every step of the patient’s health journey from prevention to diagnosis and treatment, as well as help healthcare organizations make the world a healthier place.”
On Sunday November 26 and Monday, November 27 at 11:00am CST, Fujifilm will host a product unveiling of its new compact, 128-slice CT system, the FCT iStream*. The FCT iStream leverages vision modeling iterative reconstruction (IPV) for up to 83% dose reduction and intelliODM, an organ-based tube current that reduces dose 30% without compromising image quality. The system is able to capture 60 images per second, contributing to a quicker scanning experience for the patient and streamlined workflow for the clinician.
In addition to the product unveiling, RSNA attendees will get to experience hands on demonstrations with the following new medical innovations from Fujifilm:
Also at Fujifilm’s Booth #1929, the company will be celebrating 20 years of leadership in ultrasound elastography and will be conducting live scans with Fujifilm’s ARIETTA DeepInsight line. In 2003, Fujifilm released the world’s first commercially available ultrasound platform with real-time tissue elastography. The ARIETTA 750DI, ARIETTA 650DI and ARIETTA 850DI* leverage Fujifilm’s DeepInsight technologies, which use cognitive technology to distinguish between echo signals and electrical noise, to selectively extract the signals necessary for deep tissue visualization. This results in high quality images, even from deep and challenging regions of interest, to support more accurate ultrasound procedures.
Visit Fujifilm at RSNA 2023 to learn more about the company’s latest diagnostic and enterprise imaging advancements that can redefine the way clinicians see diseases today and inspire the imaging techniques of tomorrow. Join Fujifilm in person at booth #1929 at RSNA and follow FUJIFILM Healthcare Americas Corporation on LinkedIn and X for #RSNA23 updates throughout the event.
*Will be available in the U.S. upon completion of regulatory requirements.
FUJIFILM Healthcare Americas Corporation is a comprehensive healthcare company that has an extensive range of technology and expertise in the detection, diagnosis and treatment of diseases. Fujifilm’s innovative medical imaging portfolio includes solutions for digital radiography, mammography, CT, MRI, ultrasound, gastroenterology, pulmonology, endosurgery, and minimally invasive surgery. The award-winning Synapse® Enterprise Imaging portfolio provides healthcare professionals with the cross-departmental imaging and data access needed to deliver a complete patient record. Fujifilm’s AI initiative, REiLI®, combines Fujifilm’s rich image-processing heritage with cutting-edge innovations to inspire clinical confidence and combat burnout. The In-Vitro Diagnostic portfolio provides the gold standard of molecular based immunoassay technology for liver surveillance, cutting edge clinical diagnostic chemicals for leading laboratories and diagnostic chemicals for OEM white labelling products. The company is headquartered in Lexington, Massachusetts. Click here for more information.
FUJIFILM Holdings Corporation, Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver “Value from Innovation” in our products and services in the business segments of healthcare, materials, business innovation, and imaging. Our relentless pursuit of innovation is focused on providing social value and enhancing the lives of people worldwide. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information about Fujifilm’s Sustainable Value Plan 2030,click here. For the year ended March 31, 2023, the company had global revenues of approximately 2.9 trillion yen (21 billion USD at an exchange rate of 134 yen/dollar). For more information, please visit:www.fujifilmholdings.com.